Syncom Formulations (India) Limited Asset Resilience Ratio

Latest as of September 2025: 31.53%

Syncom Formulations (India) Limited asset resilience ratio. Syncom Formulations (India) Limited (SYNCOMF) has an Asset Resilience Ratio of 31.53% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SYNCOMF cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Rs1.44 Billion

≈ $15.55 Million USD Cash + Short-term Investments

Total Assets

Rs4.56 Billion

≈ $49.32 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of Syncom Formulations (India) Limited (2006–2025)

Asset resilience ratio of Syncom Formulations (India) Limited from 2006 to 2025. This chart shows how Syncom Formulations (India) Limited's Asset Resilience Ratio has changed over time. Read Syncom Formulations (India) Limited (SYNCOMF) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Syncom Formulations (India) Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Syncom Formulations (India) Limited total assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs0.00	0%
Short-term Investments	Rs1.44 Billion	31.53%
Total Liquid Assets	Rs1.44 Billion	31.53%

Asset Resilience Insights

Very High Liquidity: Syncom Formulations (India) Limited maintains exceptional liquid asset reserves at 31.53% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Syncom Formulations (India) Limited Industry Peers by Asset Resilience Ratio

Compare Syncom Formulations (India) Limited's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Galderma Group N SW:GALD	Drug Manufacturers - Specialty & Generic	3.56%
Enzymatica publ AB ST:ENZY	Drug Manufacturers - Specialty & Generic	22.17%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	9.04%
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	Drug Manufacturers - Specialty & Generic	47.16%
Kangmei Pharmaceutical Co Ltd SHG:600518	Drug Manufacturers - Specialty & Generic	0.00%
Walvax BioTech SHE:300142	Drug Manufacturers - Specialty & Generic	2.20%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%

Syncom Formulations (India) Limited Asset Resilience Ratio by Year (2006–2025)

Syncom Formulations (India) Limited asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for Syncom Formulations (India) Limited.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	21.59%	Rs892.16 Million ≈ $9.65 Million	Rs4.13 Billion ≈ $44.69 Million	+4.74pp
2024-03-31	16.85%	Rs681.82 Million ≈ $7.37 Million	Rs4.05 Billion ≈ $43.76 Million	-1.68pp
2023-03-31	18.53%	Rs700.17 Million ≈ $7.57 Million	Rs3.78 Billion ≈ $40.86 Million	+5.54pp
2022-03-31	12.99%	Rs400.31 Million ≈ $4.33 Million	Rs3.08 Billion ≈ $33.33 Million	-11.47pp
2021-03-31	24.46%	Rs713.42 Million ≈ $7.72 Million	Rs2.92 Billion ≈ $31.54 Million	+24.26pp
2020-03-31	0.20%	Rs3.62 Million ≈ $39.15K	Rs1.81 Billion ≈ $19.52 Million	-0.09pp
2019-03-31	0.30%	Rs5.11 Million ≈ $55.25K	Rs1.73 Billion ≈ $18.71 Million	-2.72pp
2018-03-31	3.01%	Rs51.49 Million ≈ $556.83K	Rs1.71 Billion ≈ $18.49 Million	+2.63pp
2017-03-31	0.38%	Rs6.90 Million ≈ $74.62K	Rs1.80 Billion ≈ $19.48 Million	+0.31pp
2015-03-31	0.08%	Rs1.07 Million ≈ $11.55K	Rs1.38 Billion ≈ $14.88 Million	-1.23pp
2006-03-31	1.31%	Rs6.20 Million ≈ $67.04K	Rs473.07 Million ≈ $5.12 Million	--

pp = percentage points

About Syncom Formulations (India) Limited

NSE:SYNCOMF India Drug Manufacturers - Specialty & Generic

Market Cap

$195.59 Million

Rs18.09 Billion INR

Market Cap Rank

#16443 Global

#842 in India

Share Price

Rs19.24

Change (1 day)

-5.73%

52-Week Range

Rs10.30 - Rs26.18

All Time High

Rs26.77